newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Aligos Therapeutics announced on December 12, 2025, that its Compensation Committee granted non-qualified stock options for 14,100 shares to newly hired employees on December 9, 2025.
  • The Inducement Grants were awarded under the Company's 2024 Inducement Plan to comply with Nasdaq Listing Rule 5635(c)(4) for individuals not previously employed by Aligos.
  • The exercise price per share for the grants equals the closing price of Aligos common stock on the Grant Date.
  • Shares subject to the Inducement Grant will vest over a four-year period, with 25% vesting on the first anniversary of the Grant Date and the remainder vesting in equal monthly installments contingent on continued employment.
  • Aligos is a clinical stage biopharmaceutical company focused on developing therapies for liver diseases, viral diseases, chronic hepatitis B, obesity, MASH, and coronaviruses.